trending Market Intelligence /marketintelligence/en/news-insights/trending/rxg65_gnj4-b1dpn7w-vfa2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

GlaxoSmithKline adds 2 execs to board

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


GlaxoSmithKline adds 2 execs to board

GlaxoSmithKline PLC named CEO Designate Emma Walmsley and President of R&D Patrick Vallance to the board as executive directors, effective Jan. 1, 2017.

Stacey Cartwright will step down from the board, effective Dec. 31. She leaves after serving for almost 6 years as a nonexecutive director.

In addition, Andrew Witty and Moncef Slaoui will step down from the board March 31, 2017. Slaoui will serve as adviser to the company and the board from April 1, 2017, until his retirement June 30, 2017.